Rheumnow Podcast

By Dr. CushMedicine Health & Fitness

Favorites
58
Followers
Typical duration
28 min
per episode

Based on Podcast App listening data

Rheumnow Podcast episodes

March 20 Rheumatoid Arthritis Faculty Panel Q&A
Rheumatoid Arthritis Faculty Panel Q&A
33 min
March 20 ILD in RA - Recent Advances. Dr. Jeffrey Sparks
ILD in RA - Recent Advances. Dr. Jeffrey Sparks
31 min
March 20 The Mucosal Hypothesis of Rheumatoid Arthritis. Dr. Kristin Demoruelle
The Mucosal Hypothesis of Rheumatoid Arthritis. Dr. Kristin Demoruelle
32 min
March 20 Mortality in Rheumatoid Arthritis: A Story of Decline, Delay, or Plateau? Dr. Elena Myasoedova
Mortality in Rheumatoid Arthritis: A Story of Decline, Delay, or Plateau? Dr. Elena Myasoedova
31 min
March 13 Poets Know It (3.13.2026)
Dr. Jack Cush reviews the news, regulatory decisions and new journal articles.
26 min
March 06 UBER Rheumatology Ride (3.6.2026)
Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com
32 min
March 02 Early Decisions and Impact: An IL-23 Inhibitor in Bio-Naive Patients With PsA
Sponsored by AbbVie Medical Affairs + Health Impact 
14 min
February 28 DERM on RheumNow PODCAST (February 2026)
The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects.
Features Dr. Jack Cush, Editor at RheumNow.com.
SHOW NOTES
FDA sent a complete response letter to AstraZeneca on their application (BLA) for anifrolumabs (Saphnelo) subcutaneous use in SLE. Despite a positive TULIP-SC trial & EU approval of SC-anifrolumab, FDA & sponsor still have to work things out. CRL reasons are unknown https://t.co/3dNwEyolrj
Review of Calcinosis Cutis - Surgical intervent. most effective (excision, curettage, laser ablation, etc). Medical measures inconsistently, partially effective, best if used early & localized (CCB, TCN, probenecid, immunomodulation, biologics, colchicine, NA thiosulfate, & JAKi https://t.co/rv0hQBv6nX
Systematic Review of Targeted Rx for Systemic Sclerosis: from 32 RCTs & 2036 pts Rx w/ 23 targeted agents. Guselkumab had greatest effect on mRSS, followed by tofacitinib, inebilizumab, & baricitinib. For FVC, B-cell Rx (belimumab, RTX) had highest efficacy https://buff.ly/vHOSRws
Dermatomyositis outcomes w/ 2475 pts (claims) & 1196 pts (EHR). Half had myositis panels & 35% had + MSAbs. Steroid use common in 69% & 74%. HCQ, MTX, MMF. Outocmes (per 1000PYs) wereL all-cause hospitalisation 92, malignancy 15.3, ILD 6.4, and myocarditis 2.1 https://t.co/DJqKGNGX76
Danish DERMBIO registry of psoriasis pts Rx w/ biologics. Among 3790 bionaive pts ustekinumab had best 1-5 yr survival vs (ADA & SEC). In 3403 bioexperienced pts, bimekizumab, guselkumab, & risankizumab had highest 2-year drug survival rate. https://t.co/TInyLPMYkb
Real-world study of 1202 #PsA pts shows that secukinumab retention rates were lower w/ smoking (79%/73%/72% in never/former/current smokers) but not w/ obesity (72%/77%/77% in normal/overweight/obese), Adh HR signif. higher w/ former (1.32) & current smokers (1.27) https://t.co/1REWmod73W
Together PSO Trial - Combination Ixekizumab and Tirzepatide Today Lilly announced top line results of the TOGETHER-PsO open-label, Phase 3b trial demonstrating the significant benefits of concomitant ixekizumab (IXE: an IL-17A inhibitor) and tirzepatide (TIR: GLP-1agonist) over https://t.co/YWCjN2NyGM
13 min
February 27 SATISFACTION (2.27.2026)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
25 min
February 20 Referral Rules to Live By (2.20.2026)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Highlights include referral rules, combination biiologics in psoriasis and don't use JAK inhibitors in pregnancy.
21 min